Trials / Active Not Recruiting
Active Not RecruitingNCT06903338
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Vir Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tobevibart | Tobevibart administered by subcutaneous injection |
| DRUG | Elebsiran | Elebsiran administered by subcutaneous injection |
Timeline
- Start date
- 2025-03-12
- Primary completion
- 2026-12-31
- Completion
- 2031-05-01
- First posted
- 2025-03-30
- Last updated
- 2026-04-08
Locations
39 sites across 10 countries: United States, Canada, Georgia, Germany, Moldova, New Zealand, Pakistan, Romania, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06903338. Inclusion in this directory is not an endorsement.